

# Review of: "Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients"

Giuseppina Campisi<sup>1</sup>

<sup>1</sup> BiND, University of Palermo, Italy

Potential competing interests: No potential competing interests to declare.

Dear authors and readers, I consider the points touched upon by Fusco et al. to be very crucial in clarifying and predicting the real incidences of MRONJ. It would be very important to receive from the authors of the paper "*Incidence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study*" this in-depth analysis with respect to their very interesting data, especially on the analysis of patients divided on the basis of the start year of treatment (e.g., period 2000-2005, 2006-2010, 2011-2015, and 2016-2020), and also information on whether the anti-resorptive therapy started from the primary cancer diagnosis or the diagnosis of bone metastases. Thanks for this opportunity.